1069087-66-6

Basic information

• Product Name: (4S)-N-{[2-chloro-3-(trifluoromethyl)phenyl]methyl}-1,3-dimethyl-2-oxo-4-imidazolidinecarboxamide
• Synonyms: (4S)-N-{[2-chloro-3-(trifluoromethyl)phenyl]methyl}-1,3-dimethyl-2-oxo-4-imidazolidinecarboxamide
• CAS NO: 1069087-66-6
• Molecular Weight: 349.74
• Mol File: 1069087-66-6.mol

Chemical Properties

• CAS DataBase Reference: (4S)-N-{[2-chloro-3-(trifluoromethyl)phenyl]methyl}-1,3-dimethyl-2-oxo-4-imidazolidinecarboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: (4S)-N-{[2-chloro-3-(trifluoromethyl)phenyl]methyl}-1,3-dimethyl-2-oxo-4-imidazolidinecarboxamide(1069087-66-6)
• EPA Substance Registry System: (4S)-N-{[2-chloro-3-(trifluoromethyl)phenyl]methyl}-1,3-dimethyl-2-oxo-4-imidazolidinecarboxamide(1069087-66-6)

Safety Data

• Hazardous Substances Data: 1069087-66-6(Hazardous Substances Data)

Upstream product

• 1069090-18-1 methyl (S)-1,3-dimethyl-2-oxo-4-imidazolidinecarboxylate 
• 90242-55-0 Methyl (4S)-3-<(benzyloxy)carbonyl>-1-methyl-2-oxoimidazolidine-4-carboxylate 
• 168399-09-5 Methyl (4S)-1-Methyl-2-oxoimidazolidine-4-carboxylate 
• 1069090-20-5 (S)-1,3-dimethyl-2-oxo-4-imidazolidinecarboxylic acid 
• 39226-96-5 2-chloro-3-(trifluoromethyl)benzylamine 

Relevant articles and documents

Identification of 2-oxo-N-(phenylmethyl)-4-imidazolidinecarboxamide antagonists of the P2X7 receptor

A backup molecule to compound 2 was sought by targeting the most likely metabolically vulnerable site in this molecule. Compound 18 was subsequently identified as a potent P2X7 antagonist with very low in vivo clearance and high oral bioavailability in all species examined. Some evidence to support the role of P2X7 in the etiology of pain is also presented.

IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS

The present invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof: The compounds or salts modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor (P2X7 receptor antagonists). The invention also provides the use of such compounds or salts, or pharmaceutical compositions thereof, in the treatment or prevention of disorders / diseases mediated by the P2X7 receptor, for example pain, inflammation or a neurodegenerative disease, in particular pain such as inflammatory pain, neuropathic pain or visceral pain.